Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat

Psychopharmacology

Volumn 165, Issue 2, 2003, Pages 128-135

  Martin, Renee S ^a   Secchi, Robert L ^a   Sung, Eric ^a   Lemaire, Martine ^b   Bonhaus, Douglas W ^a   Hedley, Linda R ^a   Lowe, David A ^a  

^a ROCHE BIOSCIENCE   (United States)

^b Porsolt and Partners Pharmacology   (France)

Author keywords

Cannabinoid; CB1; Pre pulse inhibition; Psychosis; SR 141716A

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; APOMORPHINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CLOZAPINE; DEXAMPHETAMINE; DIZOCILPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHEDELIC AGENT; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; AUDITORY STIMULATION; CHANNEL GATING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SELECTIVITY; EXPERIMENT; HYPERACTIVITY; MALE; METHODOLOGY; NONHUMAN; OBSERVATION; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR BLOCKING; SENSORIMOTOR FUNCTION; STANDARD; STARTLE REFLEX; STEREOTYPY; STIMULATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; AROUSAL; ATTENTION; BEHAVIOR, ANIMAL; CYCLOHEXANOLS; DEXTROAMPHETAMINE; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MALE; MOTOR ACTIVITY; PIPERIDINES; PSYCHOSES, SUBSTANCE-INDUCED; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STARTLE REACTION; STEREOTYPED BEHAVIOR;

EID: 0037221846     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1240-x     Document Type: Article

References (32)

1. Arvanitis L, Bauer D, Rein W (2001) Efficacy and tolerability of four novel compounds in schizophrenia: Results of the metatrial project. 40th Annual Meeting of American College of Neuropsychopharmacology, abstract book, p 178
2. Bakshi VP, Swerdlow NR, Geyer MA (1994) Clozapine antagonizes, phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271:787-794
3. Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Arch Gen Psychiatry 47:181-188
4. Braff DL, Grillon C, Geyer MA (1992) Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49:206-215
5. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163
6. Chaperon F, Thiebot MH (1999) Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13:243-281
7. Costall B, Marsden CD, Naylor RJ, Pycock CJ (1997) Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei. Brain Res 123:89-111
8. Davis M, Sheard MH (1975) Effects of lysergic acid diethylamide (LSD) on temporal recovery (pre-pulse inhibition) of the acoustic startle response in the rat. Pharmacol Biochem Behav 3:861-868
9. 1 receptors by cannabinoids. Eur J Neurosci 10:2825-2830
10. 1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85:468-471
11. Geyer MA, Swerdlow NR, Mansbach RS, Braff DL (1990) Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25:485-498
12. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology 156:117-154
13. Hoffman DC, Donovan H, Cassella JV (1993) The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist, MK-801. Psychopharmacology 111:339-344
14. 1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58:322-328
15. Johns A (2002) Psychiatric effects of cannabis. Br J Psychiatry 178:116-122
16. Kreitzer AC, Regehr WG (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717-727
17. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1-2
18. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. NeuroReport 10:1665-1669
19. Maneuf YP, Brotchie JM (1997) Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120:1397-1398
20. Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299-308
21. 1 receptor antagonist SR141716A on the behaviour of pigeons and rats. Psychopharmacology 124:315-322
22. 9-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. Br J Pharmacol 130:1201-1210
23. 1) receptors by SR141716 selectively antagonises drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology 144:144-150
24. Schlicker E, Kathmann M (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565-572
25. Simon P, Chermat R, Fosset MT, Boissier JR (1972) Adrenergic blocking agents and amphetamine or apomorphine induced stereotyped behavior in rats. Psychopharmacologia 23:357-364
26. Skosnik PD, Spatz-Glenn L, Park S (2001) Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res 48:83-92
27. Snyder SH (1976) The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am J Psychiatry 133:197-202
28. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139-154
29. Swerdlow NR, Geyer MA, Braff L (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: Current knowledge and future challenges. Psychopharmacology 156:194-215
30. Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C (2000) Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 97:87-97
31. Talbott JA, Teague JW (1969) Marihuana psychosis. Acute toxic psychosis associated with the use of cannabis derivatives. JAMA 210:299-302
32. Zygmunt PM, Petersson J, Andersson DA, Chuang HH, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457